Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience
Sign Up to like & getrecommendations! Published in 2018 at "Hepatology International"
DOI: 10.1007/s12072-018-9861-2
Abstract: IntroductionNew regimens involving direct-acting antiviral agents have recently been approved for the treatment of HCV. Our aim was to assess the efficacy and safety of 12 or 24 weeks of Sofosbuvir 400 mg plus Daclatasvir 60 mg, with… read more here.
Keywords: genotype patients; treatment; receiving weeks; without ribavirin ... See more keywords
Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2017.1307204
Abstract: Abstract Background: A phase III trial evaluated the efficacy and safety of Daklinza (daclatasvir or DCV) in combination with sofosbuvir (SOF) for treatment of genotype (GT) 3 hepatitis C virus (HCV) patients. Aim: This study… read more here.
Keywords: combination; treatment; treatment genotype; cost effectiveness ... See more keywords